Ariad Pharmaceuticals: The Winning Streak Continues (ARIA)
Shares of Ariad Pharmaceuticals (NASDAQ:ARIA) traded today at $10.72, breaking its 52-week high. This new high was reached on below average trading volume as 632,000 shares traded hands, while the average 30-day volume is approximately 3.3 million shares.
In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $4.37 and a high of $10.72 and are now at $10.66, 144% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.5% while the 50-day MA has advanced 2.4%.
Ariad Pharmaceuticals (NASDAQ:ARIA) is currently priced 18.4% above its average consensus analyst price target of $8.70. Ariad Pharmaceuticals shares have support at the 200-day moving average (MA) of $6.57 and additional support at the 50-day MA of $6.55.
ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers.
SmarTrend recommended that subscribers consider buying shares of Ariad Pharmaceuticals on July 22nd, 2016 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $8.07. Since that recommendation, shares of Ariad Pharmaceuticals have risen 31.2%. We continue to monitor ARIA for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.
Keywords: 52 week high/lows ariad pharmaceuticals